GlassScriptPhysician profile
Mark J Godat
NPI 1134281405
$15,006.99
in general payments reported to CMS, 2019-2025
60 companies · $1,571 in 2025
The $1,571 reported for 2025 was more than what 93% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,559 · 2020: $969 · 2021: $1,550 · 2022: $1,939 · 2023: $1,691 · 2024: $1,729 · 2025: $1,571.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,626 · Debt Forgiveness: $181 · Education: $180 · Gift: $4.37.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,625.83 |
| Debt Forgiveness | $180.71 |
| Education | $180.00 |
| Gift | $4.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Minerva Surgical, INC | $3,040.99 | 2019-2024 | |
| Abbvie INC. | $2,144.43 | 2019-2025 | |
| Amgen INC. | $1,698.63 | 2019-2025 | Evenity, Prolia, Prolia |
| Duchesnay USA Incorporated | $1,148.00 | 2019 | |
| Novo Nordisk INC | $797.95 | 2019-2025 | Wegovy |
| Millicent US INC | $589.89 | 2020-2025 | Intrarosa, Femring |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $507.62 | 2019-2025 | Trulance, Xifaxan, Relistor |
| Pfizer INC. | $338.48 | 2019-2024 | |
| Radius Health, INC. | $338.38 | 2019-2025 | Tymlos |
| Idorsia Pharmaceuticals US INC | $325.59 | 2022-2025 | Quviviq, Quviviq |
| Mayne Pharma Commercial LLC | $290.70 | 2021-2025 | |
| Astellas Pharma US INC | $260.25 | 2023-2025 | Veozah |
| Gynesonics, INC. | $257.85 | 2022 | |
| Therapeuticsmd, INC. | $228.38 | 2019-2022 | |
| Amneal Pharmaceuticals LLC | $219.33 | 2021-2025 | Unithroid |
Show all 59 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$5.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Godat listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.